Article Per Year (5 Year)
p-Index From 2021 - 2026
2.813
P-Index
This Author published in this journals
All Journal Indonesian Journal of Obstetrics & Gynecology Science Jurnal Medik Veteriner Jurnal Respirologi Indonesia Journal of the Indonesian Medical Association : Majalah Kedokteran Indonesia SCRIPTA SCORE Scientific Medical Journal Respiratory Science JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia
Simanjuntak, Arya Marganda
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Education Health Professions Medicine & Pharmacology Public Health Veterinary

Published : 18 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 18 Documents
Search

 1   2 
Characteristics of Lung Cancer Patients with Brain Metastases based on Baseline Head Computerized Tomography (CT)-scan in Arifin Achmad Hospital October 2022 - June 2023 Sari, Rezki Permata; Fauzi, Zarfiardy Aksa; Simanjuntak, Arya Marganda
Respiratory Science Vol. 4 No. 2 (2024): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v4i2.108

Abstract

Background: The majority of lung cancer cases are often discovered at a late stage because it frequently develops without symptoms in the early stages. Many lung cancer deaths are caused by metastases to other organs. The purpose of this study was to examine the features of lung cancer patients with brain metastases using baseline CT scan data. Method: Between October 2022 and June 2023, a cross-sectional study was conducted at the Arifin Achmad Hospital in Pekanbaru on all newly diagnosed lung cancer patients with brain metastases who also met the inclusion and exclusion criteria. Results: Eight subjects of lung cancer with brain metastasis were found from 49 patients. All subjects were male with age mostly in between 40 and 60 years. Three subjects (37.5%) were Squamous Cell Carcinoma (SCC), four subject (50%) were adenocarcinoma and 1 (12.5%) were SCLC. Conclusion: This study discovered that 16.3% of patients who met the inclusion criteria had lung cancer with brain metastases. Further research should be done on a cohort study and a preventive strategy for lung cancer with brain metastases.
Profile of COVID-19 Patients at Arifin Achmad Hospital, Riau Province Between January 2021 and June 2021 Syaf, Syarlidina; Adrianison, Adrianison; Simanjuntak, Arya Marganda
Respiratory Science Vol. 4 No. 3 (2024): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v4i3.113

Abstract

Background: Coronavirus disease 2019 (COVID-19) is a disease caused by a new coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously called 2019 novel coronavirus) which was first identified in Wuhan City, Hubei Province, China. World Health Organization declared COVID-19 a global pandemic on March 12 2020 and until June 2021 there were 184 million cases with 3.9 million deaths worldwide. In Indonesia, until June 2021 there have been 2.2 million positive cases of COVID-19 and 60 thousand deaths. Method: The data collection method used in this study is a descriptive cross-sectional approach. According to the inclusion criteria, samples were collected for six months, and the results are shown as a distribution table. Results: The number of patients treated for the period from January to June 2021 totaled 1,442 people. The highest number of patients treated according to age was middle-aged (40.6%) and children (1.1%). The number of COVID-19 patients based on length of treatment from January to June was suspected (2-4 days) 28.13%, confirmed (5–45 days) 61.6%, discharged at own request 9.78%, referred 0.48%. The number of cured COVID-19 patients being treated at the Arifin Achmad Hospital in Riau Province from January to June 2021 has recovered 75.9% and died 13.7%. Conclusion: In Indonesia, until June 2021 there have been 2.2 million positive cases of COVID-19 and 60 thousand deaths. Riau Province as of June 2021 has recorded 70,520 confirmed cases and 1,931 deaths. The Arifin Achmad Pekanbaru General Hospital from March 2020 to June 2021 recorded 1,524 confirmed cases and 148 deaths.
Current Knowledge of Mycobacterium Other Than Tuberculosis (MOTT) in this Current Era: Definition, Taxonomy, and Diagnose Indriani, Sri Indah; Pratiwi, Adelia; Simatupang, Elvando Tunggul Mauliate; Simanjuntak, Arya Marganda
Respiratory Science Vol. 4 No. 3 (2024): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v4i3.122

Abstract

Globally, Pulmonary Tuberculosis (PTB) remains a health concern, with an annual increase in cases. Indonesia is the second-highest contributor to PTB cases globally, below India, which also saw an increase in cases, particularly after the COVID-19 pandemic. Nontuberculous Mycobacteria (NTM) infections contribute to the increase in PTB cases through misdiagnosis and overlapping conditions. The occurrence of changes in the composition of NTM species in the Mycobacterium genus is the premise for updating the diagnosis of NTM with several supporting examination modalities. Clinical, radiological, and microbiological criteria have been established by the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) for the diagnosis of NTM. The relationship between these three criteria is essential as a guideline for distinguishing infections caused by Mycobacterium tuberculosis (Mtb) from those caused by NTM.
Mepolizumab’s (Anti-Interleukin-5) Role in Severe Asthma: A Literature Review Atikanur, Atikanur; Wijaya, Dewi; Esha, Indi; Simanjuntak, Arya Marganda
Jurnal Respirologi Indonesia Vol 44 No 2 (2024)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v44i2.494

Abstract

One type of asthma that is difficult to treat is severe asthma, which is asthma that is uncontrolled even when the patient is taking medication or trigger factors. It can be treated with the finest therapy but will worsen if high-dose treatment is discontinued. Age, gender, obesity, hypersensitivity, and immunological factors are all directly related to the onset of asthma. A complicated illness, severe asthma has many clinical symptoms and treatment choices. Chronic airway inflammation and lung tissue remodeling are its defining features. This literature review aims to describe how mepolizumab works in patients with severe asthma. Mepolizumab mainly inhibits the IL-5 cytokine from binding to IL-5 receptor subunits through the nanomolar potential, which inhibits IL-5 from binding to receptors on the surface of eosinophils. In contrast to the placebo group, patients on mepolizumab had an average 50% decrease from the baseline Prednisone dosage. With Mepolizumab, the yearly exacerbation rate was 1.44 RR, while it was 2.12 RR with placebo. The injection of monoclonal antibodies, such as mepolizumab, as a form of therapy in addition to treating severe eosinophilic asthma is advised by the GINA guideline for 2022. Mepolizumab's mode of action blocks IL-5 from binding to receptors on eosinophil surfaces, which lowers eosinophil recruitment, activation, production, growth, and survival, as well as eosinophil-mediated inflammation.
Current Lung Asbestosis Approach for Diagnosis, Not Just Histopathology: A Literature Review Purnama, Nori; Esha, Indi; Adrianison, Adrianison; Simanjuntak, Arya Marganda
Jurnal Respirologi Indonesia Vol 45 No 1 (2025)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v45i1.678

Abstract

Asbestosis is characterized by diffuse interstitial fibrosis in the lungs, which is caused by breathing asbestos fibers from the crystalline or amphibole groups. The diagnosis of asbestosis, a form of pneumoconiosis, is one of the seven steps in identifying an occupational lung disease. Because there is no known cure for this condition, early detection, prevention, and education of workers and anybody in their proximity who has a risk of asbestos fiber exposure is critical. Clinical symptoms of asbestosis include weight loss, decreased appetite, and dyspnea during exertion. Clubbing fingers, cyanosis, and tachypnea are all symptoms of severe asbestosis. Bronchoalveolar lavage (BAL), histology, CT scans, HRCT, and respirometry can all help with the diagnosis. The "shaggy heart border sign" on a chest X-ray, along with the asbestos body observed in the BAL, is a reliable indicator of asbestosis. Because of the dismal prognosis and lifelong consequences, prevention is essential.
Profile of Pulmonary Tuberculosis After COVID-19 at Toba District, North Sumatra Province Simatupang, Elvando Tunggul Mauliate; Simanjuntak, Arya Marganda; Yovi, Indra; Simbolon, Rohani Lasmaria; Fauzi, Zarfiardy Aksa
Jurnal Respirologi Indonesia Vol 44 No 4 (2024)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v44i4.716

Abstract

Background: Worldwide cases of pulmonary tuberculosis (PTB) have significantly increased since the COVID-19 pandemic. Indonesia accounted for 6,811,818 of the 767,518,723 cases reported by the World Health Organization. While the Indonesian Ministry of Health reported 824,000 cases, the Global Tuberculosis Report in 2022 reported 10.6 million cases. The pandemic has hampered the goal of eliminating PTB globally, with cases diagnosed after COVID-19 having a 7.15-fold increased risk of contracting the illness.Methods: This cross-sectional study was conducted using total sampling to identify the profile of patients with PTB after having COVID-19 based on age, gender, classification, and type of PTB, as well as the duration of occurrence of PTB after COVID-19. The data collected were from COVID-19 patients from 2020 to 2022, then compared with PTB data. All data were compared to ensure that COVID-19 and PTB patient data were the same.Results: Of the 2544 patients recorded, 29 (1.1%) were infected with PTB after COVID-19 infection. The mean age of patients was 34±18.9 and was dominated by men (68.9%). Most of the cases were drug-sensitive TB (96.6%) and clinically diagnosed TB (55.2%). Age had a statistically significant association with the occurrence of TB cases after COVID-19 infection (P<0.0001). The mean time from the initial diagnosis of COVID-19 to the diagnosis of confirmed TB was approximately 203±34.3 days (6.7 months).Conclusion: After COVID-19, patients have the potential to be infected with TB. Screening former COVID-19 patients can be one solution to finding early cases of PTB.
COVID-19 dan Tuberkulosis Paru, Antara Koinfeksi dan Reaktivasi dari Laten Tuberkulosis: Sebuah Kajian Sistematis Simanjuntak, Arya Marganda; Yovi, Indra; Marbun, Patricia Dean Ully; Elisabet, Adinda
Majalah Kedokteran Indonesia Vol 73 No 2 (2023): Journal of The Indonesian Medical Association - Majalah Kedokteran Indonesia, Vo
Publisher : PENGURUS BESAR IKATAN DOKTER INDONESIA (PB IDI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.47830/jinma-vol.73.2-2023-1006

Abstract

Introduction: Globally, cases of pulmonary tuberculosis (PTB) are rising by 4%, while new cases have declined in many nations, most notably by 14% in Indonesia. During the COVID-19 pandemic, the number of undiagnosed and untreated PTB patients could rise and infect more people. In particular, CD8+ lymphocytes were decreased in COVID-19. Perhaps this is the cause of the rise in cases, but there is no data to show it. Aim: Determine current data about the PTB with COVID-19 coinfection and possible reactivation of PTB after COVID-19 infection in LTB patient. Methods: This systematic review is based on PRISMA statements using Pubmed, EBSCOHost, Science Direct and Cochrane from December 2019 to July 2022. Inclusion and exclusion criteria were set to select studies that included. We analyze risk of bias of all included studies with JBI critical appraisal tools. Results: This study had 107,425 patients in total from 20 studies. All studies were deemed to have low overall author bias risks. A critical component of PTB defense is CD8+. By reducing lymphocytes, COVID-19 can encourage the growth of PTB, which might therefore result in coinfection or the reactivation of existing PTB. Conclusion: COVID-19 possibly increase case of PTB in form of co-infection or reactivation of PTB in LTB patients. This needs special attention for patients that have infected by COVID-19 to followed up for risk developing PTB.
Bagaimana Bekas Tuberkulosis Dapat Menginduksi Kanker Paru? Simatupang, Elvando Tunggul Mauliate; Simanjuntak, Arya Marganda; Yovi, Indra; Simbolon, Rohani Lasmaria; Munir, Sri Melati; Wijaya, Dewi
Majalah Kedokteran Indonesia Vol 73 No 6 (2023): Journal of The Indonesian Medical Association - Majalah Kedokteran Indonesia, Vo
Publisher : PENGURUS BESAR IKATAN DOKTER INDONESIA (PB IDI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.47830/jinma-vol.73.6-2024-1087

Abstract

In 2022, there will be 10.6 million cases of tuberculosis, which is a serious problem worldwide. Thailand's cohort research after the COVID-19 pandemic found a 7-fold risk of tuberculosis infection in COVID-19 patients, pointing to a probable rise in TB cases. In order to completely eradicate TB, care must be given to patients both before and after infection, guaranteeing public health against TB infection.1,2
Co-Authors Adrianison, Adrianison Arfianti Arfianti Atikanur, Atikanur Azis, Abdurrahman Elisabet, Adinda Enikarmila Asni Erdayani, Rita Esha, Indi Fakhrizal, Edy Ginting, Heri Krisnata Girsang, Agnes Ivana Hutapea, Anastasya INDRA YOVI Indri, R.Melda Indriani, Sri Indah Jully Handoko Latifah Humairoh Marbun, Patricia Dean Ully Martarita, Evitrie Nababan, Heru Maranatha Patresia, Putri Leony Pengsakul, Theerakamol Pratiwi, Adelia Purnama, Nori Rian Maulana, Rian Rohani Lasmaria Simbolon, Rohani Lasmaria Ruthcinthamy, Stevany Risdewanty S, Donel Sari, Rezki Permata Simatupang, Elvando Tunggul Mauliate Soedarmanto Indarjulianto Sri Melati Munir Susana, Yuli Suyanto Suyanto Suyanto Syaf, Syarlidina Veronica, R.Merlinda Wijaya, Dewi Yuni Eka Anggraini, Yuni Eka Yusdiana Zarfiardy Aksa Fauzi